Table 2.

Percent overweight and change from baseline (Δ) across study visits by treatment group^*

	Percent overweight and Δ			Pairwise comparison P value
	M	M+R	M+L	M vs. M+R	M vs. M+L	M+R vs. M+L
Baseline	80.1 ± 38.1	80.2 ± 38.3	74.6 ± 36.4
n at baseline	193	201	201
Month 6	79.2 ± 38.3	81.1 ± 39.3	70.7 ± 37.4
Δ 6-0	−0.9 ± 8.3	+0.8 ± 8.9	−3.9 ± 9.2	0.1276	0.0069	<.0001
Month 12	76.8 ± 40.0	84.1 ± 41.1	70.7 ± 38.7
Δ 12-0	−2.0 ± 10.9	+3.0 ± 12.4	−4.2 ± 11.6	<.0001	0.1272	<.0001
Month 24	77.4 ± 41.8	85.6 ± 38.9	72.4 ± 39.7
Δ 24-0	−2.4 ± 14.4	+4.3 ± 17.4	−33 ± 14.5	<.0001	0.6409	<.0001

^*Mean ± SD are presented. The three treatment groups are the following: metformin monotherapy (M), metformin plus rosiglitazone (M+R), and metformin plus intensive lifestyle (M+L). The P values were calculated from repeated measures models testing for Pairwise treatment differences in percent overweight change during the first 2 years of the study. The P values presented are from adjusted models for baseline percent overweight, time, treatment, sex, age at baseline, race/ethnicity, percent overweight change during run-in, and an interaction term for time-by-treatment.